In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sugen Inc.

Division of Pfizer Inc.

Latest From Sugen Inc.

Appointments: Synthorx, BTG, Pertinax, Realm, Breath, Aerie, iOnctura, Inflazome and NBE

The week's round-up includes a new CEO at Synthorx Inc., new sales executives at Aerie Pharmaceuticals and board appointments at BTG, Pertinax Pharma, Realm Therapeutics, Breath Therapeutics, iOnctura, NBE Therapeutics and Inflazome.

Appointments BioPharmaceutical

Depomed CEO, Two Board Members Out In Settlement With Investor

Starboard has been trying to replace Depomed management and add its own members to the specialty pharma company's board since at least April 2016. This is the investor's second settlement with the pain and neurology specialist.

Commercial Companies

Blueprint Medicines: A New Twist On Kinase Discovery

The convergence of maturing technology, growing industry demand for combination therapy, and regulatory innovation have given rise to Blueprint Medicines, a pure-play kinase specialist that aspires to become a US-focused cancer company.

BioPharmaceutical Business Strategies

Betta Makes First U.S. Investment, Gains Oncology Asset

The targeted cancer therapeutics venture Xcovery has received a major investment from China's Betta Pharma as part of a licensing deal for a clinical stage oncology asset.

BioPharmaceutical China
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Pfizer Inc.
  • Senior Management
  • Stephen Evans-Freke, CEO
    Bruce E MacMillan, VP, General Counsel & Corp. Secretary
    Gerald McMahon, VP, Drug Discovery
    Sara A Courtneidge, PhD, SVP, Research
  • Contact Info
  • Sugen Inc.
    Phone: (650) 553-8300
    230 East Grand Ave.
    South San Francisco, CA 94080
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register